ストックスクリーナーアプリを入手
0.98
0.08%
0.0496
前日終値:
$0.9304
開ける：
$0.97
24時間の取引高:
6,235
Relative Volume:
0.16
時価総額：
$3.81M
収益：
-
当期純損益:
$-9.87M
株価収益率:
-0.0248
EPS:
-39.4678
ネットキャッシュフロー:
$-8.76M
1週間 パフォーマンス:
-2.52%
1か月 パフォーマンス:
-14.58%
6か月 パフォーマンス:
-21.76%
1年 パフォーマンス:
-84.88%
1日の値動き範囲:
$0.9301
$0.97
1週間の範囲:
$0.91
$0.985
52週間の値動き範囲:
$0.875
$6.76
Revelation Biosciences Inc Stock (REVB) Company Profile
名前
Revelation Biosciences Inc
セクター
電話
650-800-3717
住所
4660 LAJOLLA VILLAGE DRIVE, SAN DIEGO
Compare REVB vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
REVB
Revelation Biosciences Inc
|
0.9556 | 3.95M | 0 | -9.87M | -8.76M | -39.47 |
VRTX
Vertex Pharmaceuticals Inc
|
507.17 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
790.41 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
168.82 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
997.75 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
194.22 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Revelation Biosciences Inc (REVB) 最新ニュース
Revelation Biosciences Inc. Warrant (REVBW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Revelation Biosciences Inc (NYSE: REVB) Share Price, REVB Stock News, REVB Share Price & Updates - Kalkine
Revelation Biosciences Inc. Warrant (REVBW) Key Financial Ratios – Valuation, Profitability & More - Value Research
Revelation Biosciences (REVB) Climbs 3.13% to $1.02 as Micro-Cap Biotech Tests RangeSymmetrical Triangle - vinanet.vn
Revelation Biosciences Inc. Warrant (REVBW) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Revelation Biosciences Inc (REVBU) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
Revelation (REVB) Technicals: Ends Higher by 0.92% at $1.10 at the Close; Technical View: Traders Can Monitor the $1.04-$1.16 Range in the Current UpdateVanna Flow - vinanet.vn
Price to earnings forward of Revelation Biosciences, Inc. – NASDAQ:REVB - TradingView
Form 8K Revelation Biosciences Inc For: 19 August By Investing.com - Investing.com India
Enterprise value to EBIT forward of Revelation Biosciences, Inc. – NASDAQ:REVB - TradingView
Enterprise value to revenue forward of Revelation Biosciences, Inc. – NASDAQ:REVB - TradingView
Revelation Biosciences Grants Performance-Based Restricted Stock to CEO and CFO - Minichart
Revelation Biosciences grants restricted stock awards to CEO and CFO - Investing.com
Revelation Biosciences Grants Performance-Based Executive Stock Awards - TipRanks
Revelation Biosciences grants restricted shares to James Rolke and Chester S. Zygmont III - TradingView
Revelation Biosciences (REVB) ties CEO, CFO pay to $30–120M cap tests - Stock Titan
Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study - biospace.com
Revelation Biosciences selects CRO for phase 2/3 AKI study By Investing.com - Investing.com Canada
Revelation Biosciences selects CRO for phase 2/3 AKI study - Investing.com
Revelation Biosciences Selects Avance Clinical As Cro For Phase 2/3 Titan Study - TradingView
Revelation Biosciences (REVB) CFO gifts 416K shares - Stock Titan
Revelation Biosciences (NASDAQ: REVB) grants director 32K restricted shares - Stock Titan
Revelation Biosciences (NASDAQ: REVB) details insider trade - Stock Titan
Revelation Biosciences (REVB) insider logs stock trade in company shares - Stock Titan
Armistice Capital (REVB) discloses 4.99% Revelation Biosciences stake via Master Fund - Stock Titan
REVB Q2 2026 Earnings: Loss per Share Misses Consensus as Pre-Revenue Pipeline AdvancesCFO Commentary Report - Vinanet
Price to book forward of Revelation Biosciences, Inc. – NASDAQ:REVBW - TradingView
Price to sales forward of Revelation Biosciences, Inc. – NASDAQ:REVBW - TradingView
Revelation Biosciences, Inc. (REVBW) Stock Price, News, Quote & History - Yahoo! Finance Canada
Revelation Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Revelation Biosciences reports $3.3M net loss for Q2 2026, $11.5M cash on hand - TradingView
BRIEF-Revelation Biosciences Inc Q2 EPS USD -0.87 - TradingView
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026 - Yahoo Finance
REVELATION BIOSCIENCES 2Q 2026: Net loss $(3.32M), EPS $(0.87) — 10-Q Summary - TradingView
Revelation Biosciences (Nasdaq: REVB) posts Q2 loss and flags cash risk - Stock Titan
REVB Q2'26 Earnings: EPS estimate is (0.83) USD - TradingView
REVB: Q2 net loss widened to $3.3M; Gemini targets a $94B market with cash runway through Q1 2027 - TradingView
Revelation Biosciences Inc expected to post a loss of 83 cents a shareEarnings Preview - TradingView
Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury - New Castle News
Revelation Biosciences (NASDAQ:REVB) secures FDA agreement setting single-study path for kidney drug Gemini - Kalkine
Revelation Biosciences Inc (REVB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Revelation Biosciences Inc (REVB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Revelation Biosciences Inc (REVB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Revelation Biosciences Inc (REVB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
REVB|Revelation Biosciences Inc|Price:1.050|Chg%:-0.010 - TradingKey
Revelation Biosciences Inc (REVB) Valuation: PE, PB & Fair Value Analysis - TradingKey
TradingKey - TradingKey
Revelation Biosciences Inc (REVB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Revelation Biosciences Inc (REVB) Institutional Confidence - TradingKey
Revelation Biosciences Inc (REVB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
REVB|Revelation Biosciences Inc|Price:1.060|Chg%:-0.030 - TradingKey
Revelation Biosciences Inc (REVB) 財務データ
収益
当期純利益
現金流量
EPS
0.20%
0.79%
大文字化:
|
ボリューム (24 時間):